[144] BeOne Medicines Ltd. SEC Filing

Rhea-AI Filing Summary

BeOne Medicines Ltd. (BEIGF) filed a Form 144 notifying a proposed sale of 1,204 ADS expected to be sold on September 16, 2025 on NASDAQ with an aggregate market value of $400,053.08. The shares were originally acquired as founders' shares on November 24, 2010. The filing also discloses multiple Rule 10b5-1 sales during the past three months by related parties, including John Oyler and the Pan-Oyler Foundation, with recent individual sales on 07/09/2025 (27,802 ADS, $7,044,590.31) and other sales in June–July 2025 totaling several million dollars in gross proceeds. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 plan representation.

Positive

• None.

Negative

• Concentrated insider selling: Multiple 10b5-1 sales by John Oyler and the Pan-Oyler Foundation in June–July 2025 generated multi-million-dollar gross proceeds, which could increase share supply pressure.
• Founder sale planned: A proposed sale of 1,204 ADS (aggregate value $400,053.08) by a founder-class holder is disclosed, adding to recent insider liquidity events.

Insights

Securities Analyst

TL;DR: Multiple insider sales and a current proposed founder sale signal notable insider liquidity but not necessarily a change in company fundamentals.

The filing shows a proposed sale of 1,204 ADS by a founder-class holder and several large 10b5-1 plan sales by John Oyler and an affiliated foundation during June–July 2025, producing gross proceeds in the multi-million-dollar range. From a securities perspective, clustered insider sales and Rule 10b5-1 activity are relevant for supply dynamics and market perception. This is a disclosure of planned sales; it does not provide operational or financial performance data, so materiality to valuation depends on company size and total float.

Corporate Governance Expert

TL;DR: The disclosure reflects standard insider liquidity actions under Rule 144/10b5-1, with appropriate plan representation.

Details indicate the securities were acquired as founders' shares in 2010 and that sales are being executed under established frameworks (10b5-1 and Rule 144 notice). The signer affirms absence of undisclosed material adverse information, which is a routine but required representation. Governance implications center on communication and timing of these sales; no information in the filing indicates irregularity or regulatory noncompliance.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADS	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1204	400053.08	54564278	09/16/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADS	11/24/2010	Founders Shares	Issuer			1204	11/24/2010	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JOHN OYLER Aeschengraben 27, 21st Floor Basel V8 4051	ADS	07/09/2025	27802	7044590.31
10b5-1 Sales for PAN-OYLER FOUNDATION Aeschengraben 27, 21st Floor Basel V8 4051	ADS	07/08/2025	1661	406520.95
10b5-1 Sales for JOHN OYLER Aeschengraben 27, 21st Floor Basel V8 4051	ADS	06/23/2025	3174	830359.98
10b5-1 Sales for JOHN OYLER Aeschengraben 27, 21st Floor Basel V8 4051	ADS	06/17/2025	1460	374473.21

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does BeOne Medicines' Form 144 dated for a September 16, 2025 sale disclose?

The Form 144 notifies a proposed sale of 1,204 ADS valued at $400,053.08, expected to be sold on 09/16/2025 on NASDAQ; shares are founders' shares acquired on 11/24/2010.

Who executed recent insider sales disclosed in the filing for BEIGF?

Recent Rule 10b5-1 sales were executed by John Oyler and the Pan-Oyler Foundation, including a 07/09/2025 sale of 27,802 ADS for $7,044,590.31.

Are the disclosed insider transactions part of a trading plan?

Yes; the filing references sales under Rule 10b5-1 plans and includes the required representation that the filer did not possess undisclosed material adverse information as of the plan adoption or instruction date.

How were the ADS originally acquired that are being sold under this Form 144?

The ADS were acquired as founders' shares from the issuer on 11/24/2010.

What exchange will the proposed sale be executed on?

The filing lists NASDAQ as the named securities exchange for the proposed sale.